

Press Release

July 22nd, 2020

Home Biosciences and Institut Curie announce creation of One Biosciences

One Biosciences, a company focused on generating precision medicines by leveraging the power of single-cell¹ technologies, announced today the start of its operations. The start-up is co-founded by Institut Curie, a key player in the fight against cancer, and Home Biosciences, Europe's first biotech venture builder. One Biosciences combines access to a leading single-cell and sequencing platform, and unique computational know-how originated from Institut Curie.

One Biosciences: leveraging single-cell technologies for innovative precision medicine

One Biosciences aims to become a leader in precision therapies for difficult-to-treat diseases, leveraging the power of single-cell technologies. The Company is an integrated 'discovery engine' composed of multidisciplinary teams, gathering data scientists, clinicians and biologists. These teams focus on understanding the causes of selected diseases by grasping the heterogeneity of complex biological systems, revealing rare cell populations, and enabling the cellular mapping of such diseases. One Biosciences aims to discover transcriptomic biomarkers and new actionable targets.

The Company was co-founded by Dr. Céline Vallot, PhD, Head of the Dynamics of Epigenetic Plasticity Team at Institut Curie (UMR3244 – Institut Curie, CNRS, Sorbonne Université/ Translational Department). Dr. Vallot is an expert in multi-omics data analysis and epigenetic regulation. Her lab investigates epigenetic mechanisms in breast cancer combining cancer biology with single-cell technologies and data science. She has recently co-developed means to analyze the epigenome of cancer cells at single-cell resolution and revealed the heterogeneity of chromatin states within breast tumors. Dr. Vallot has co-founded the single-cell facility of Institut Curie and is the author of multiple scientific publications using single-cell technologies combined with data science algorithms to elucidate biological mechanisms in development and cancer.

"Single-cell approaches are a paradigm shift, enabling unprecedented granularity to understand the living at a new scale. We can now tackle problems that were previously untraceable and dare to explore novel therapeutic solutions for difficult-to-treat conditions." said **Dr. Céline Vallot**, PhD, Head of the Dynamics of Epigenetic Plasticity Team at Institut Curie.

A research collaboration to expand the technical possibilities of single-cell analysis

One Biosciences was granted a worldwide license on key technologies and know-how from Institut Curie, CNRS and Sorbonne Université, in addition to an exclusive license on dedicated single-cell computational softwares, in order to generate unique insights with cutting edge single-cell approaches. The same parties have also entered into a research collaboration to expand the technical possibilities of single-cell analysis, and thus strengthen the respective leadership positions of Institut Curie's and One Biosciences' single-cell platform.

¹ These technologies allow the analysis of single cells through microfluidic approaches, opening new perspectives for fundamental research as well as for medical applications.



“One Biosciences is a flagship company of Institut Curie, showing its ambition to support the emergence of innovative companies. It is the first venture at the crossroads of data science and single-cell analysis, which are fields of excellence of Institut Curie. We are also delighted with the strong partnership with Home Biosciences.” said **Amaury Martin**, PhD, Director of Technology Transfer and Industrial Partnerships at Institut Curie and Director of Carnot Curie Cancer.

The Company is managed by Home Biosciences' team which leads and oversees its operations. Magali Richard, co-founder of Home Biosciences, will act as CEO of the Company during the first year of operations, managing an agile project team of data scientists, in close collaboration with the teams at Institut Curie. In the coming months, One Biosciences will continue to grow its team and strike research collaborations with clinical centers of excellence to build its pipeline of potential targets, in the field of oncology and beyond.

“We are thrilled to partner with Institut Curie and Dr. Vallot's team, in order to operate a leading 'discovery engine' leveraging single-cell technologies. We are now focused on assembling a team of talented data scientists, adding projects to our pipeline, and setting up small multidisciplinary teams to explore efficiently unprecedented sets of 'omics' data.” said **Dr. Magali Richard**, PhD, co-founder of Home Biosciences and One Biosciences.

Home Biosciences: leveraging novel R&D approaches and cutting-edge technologies

One Biosciences is Home Biosciences' first of a series of projects, housed in dedicated ventures. Home Biosciences, Europe's first biotech venture builder, was founded late 2019 to build in house a robust portfolio of transformative technologies and assets in cases where there is a potential to generate well-designed drug candidates addressing unmet medical needs. Its operating model allows full focus of its ventures on scientific excellence and efficient execution to significantly expedite and derisk their discovery and development paths.

“One Biosciences is the perfect example of what Home Biosciences is thriving to achieve: build tomorrow's leaders based on cutting edge technologies and science, to deliver novel targets and first-in-class therapies, that are poised to create significant value.” said **David Schilansky**, co-founder of Home Biosciences and One Biosciences.

About One Biosciences

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences.

For more information, visit: www.onebiosciences.fr

About Institut Curie

Institut Curie, France's leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs 3,500 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud, and Orsay), working on its three missions: treatment, research, and teaching. A private foundation with public utility status, Institut Curie is authorized to receive donations and legacies, and thanks to the support of its donors, is able to make discoveries more quickly, improving treatments and quality of life for patients.

For more information, visit: www.curie.fr

About Home Biosciences

Home Biosciences, Europe's first venture builder fully dedicated to biotech, aims to identify and accelerate the development of transformative technologies and treatments addressing unmet medical needs. Home Biosciences is building in-house a portfolio of high-potential technologies and drug-candidates by leveraging strong operational guidance and drug development expertise, as well as funding resources under one roof. With each of its projects housed in dedicated ventures, its operating model allows full focus of its teams on scientific and operational excellence and rapid execution to significantly expedite and de-risk their discovery and development paths. .

For more information, visit: www.homebiosciences.com

INSTITUT CURIE: PRESS CONTACTS

Catherine Goupillon - +33 (0) 6 13 91 63 63 - catherine.goupillon-senghor@curie.fr

Elsa Champion - +33 (0) 6 16 61 75 21 - elsa.champion@curie.fr

ALIZE RP: PRESS CONTACTS FOR ONE BIOSCIENCES AND HOME BIOSCIENCES

Caroline Carmagnol - +33 (0) 6 64 18 99 59 - caroline@alizerp.com

Najette Chaib - + 33 (0) 6 18 38 11 14 - nchaib@alizerp.com

ONE BIOSCIENCES CONTACTS

Magali Richard, CEO - contact@onebiosciences.fr

HOME BIOSCIENCES CONTACTS

David Schilansky, CEO - contact@onebiosciences.fr

Magali Richard, deputy CEO - contact@onebiosciences.fr